1. Insulin receptor substrate 2 gene Gly1057Asp polymorphism is a risk factor for nonalcoholic fatty liver disease.
- Author
-
Nouri, Shadi, Mahmoudi, Touraj, Hojjati, Farzaneh, Najafabadi, Zeinab Nourmohammadi, Shafiee, Radmehr, Sayedsalehi, Shiva, Dehghanitafti, Atefeh, Ardalani, Abbas, Kohansal, Kiarash, Rezamand, Gholamreza, Asadi, Asadollah, Nobakht, Hossein, Dabiri, Reza, Farahani, Hamid, Tabaeian, Seidamir Pasha, and Zali, Mohammad Reza
- Subjects
GENETICS of disease susceptibility ,NON-alcoholic fatty liver disease ,RISK assessment ,CARRIER proteins ,RESEARCH funding ,T-test (Statistics) ,POLYMERASE chain reaction ,CHI-squared test ,DESCRIPTIVE statistics ,GENETIC polymorphisms ,RESEARCH ,DATA analysis software ,CONFIDENCE intervals ,SINGLE nucleotide polymorphisms ,DISEASE risk factors - Abstract
Objective Nonalcoholic fatty liver disease (NAFLD), which is an emerging global chronic liver disease, has a close association with insulin resistance. We aimed to determine whether the Gly1057Asp (rs1805097) polymorphism of the insulin receptor substrate 2 (IRS2) gene is associated with NAFLD. Methods Using the polymerase chain reaction-restriction fragment length polymorphism method, 135 patients with biopsy-proven NAFLD and 135 controls underwent IRS2 genotype analysis. Results Genotype and allele distributions of the IRS2 gene Gly1057Asp variant conformed to the Hardy-Weinberg equilibrium in both the case and control groups (P >.05). The Asp/Asp genotype of IRS2 gene Gly1057Asp polymorphism compared with Gly/Gly genotype was associated with a 2.1-fold increased risk for NAFLD after adjustment for confounding factors (P =.029; odds ratio = 2.10, 95% CI = 1.23-3.97). Conclusion Our findings revealed for the first time that the Gly1057Asp Asp/Asp genotype of the IRS2 gene is a marker of increased NAFLD susceptibility; however, studies in other populations are required to confirm the results. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF